Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer

Molecular and Cellular Endocrinology

Volumn 383, Issue 1-2, 2013, Pages 69-79

  Wu, Weijuan ^a   Yang, Qing ^a   Fung, Kar Ming ^a,b   Humphreys, Mitchell R ^c   Brame, Lacy S ^d   Cao, Amy ^e   Fang, Yu Ting ^a,f   Shih, Pin Tsen ^a,f   Kropp, Bradley P ^a   Lin, Hsueh Kung ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Aminobutyric acid receptor; Epidermal growth factor; Prostate cancer; Src

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ARECAIDINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PHOSPHOPROTEIN; PICROTOXIN; SRC PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BONE METASTASIS; CARCINOMA CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MALE; NUCLEOLUS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EPIDERMAL GROWTH FACTOR; PROSTATE CANCER; SRC; Γ-AMINOBUTYRIC ACID RECEPTOR;

AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; GABA AGONISTS; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISONICOTINIC ACIDS; MALE; PARACRINE COMMUNICATION; PHOSPHORYLATION; PICROTOXIN; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GABA-A; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84891096632     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.11.017     Document Type: Article

References (47)

1. Abdul M., McCray S.D., Hoosein N.M. Expression of gamma-aminobutyric acid receptor (subtype A) in prostate cancer. Acta Oncol. 2008, 47:1546-1550.
2. Adam R.M., Kim J., Lin J., Orsola A., Zhuang L., Rice D.C., Freeman M.R. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 2002, 143:4599-4608.
3. Amorino G.P., Parsons S.J. Neuroendocrine cells in prostate cancer. Crit. Rev. Eukaryot. Gene Exp. 2004, 14:287-300.
4. Azuma H., Inamoto T., Sakamoto T., Kiyama S., Ubai T., Shinohara Y., Maemura K., Tsuji M., Segawa N., Masuda H., Takahara K., Katsuoka Y., Watanabe M. G-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism. Cancer Res. 2003, 63:8090-8096.
5. Bianco R., Caputo R., Damiano V., De Placido S., Ficorella C., Agrawal S., Bianco A.R., Ciardiello F., Tortora G. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin. Cancer Res. 2004, 10:4858-4864.
6. Bonaccorsi L., Marchiani S., Muratori M., Forti G., Baldi E. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J. Cancer Res. Clin. Oncol. 2004, 130:604-614.
7. David-Pfeuty T., Nouvian-Dooghe Y. Highly specific antibody to Rous sarcoma virus src gene product recognizes nuclear and nucleolar antigens in human cells. J. Virol. 1995, 69:1699-1713.
8. Di Lorenzo G., Tortora G., D'Armiento F.P., De Rosa G., Staibano S., Autorino R., D'Armiento M., De Laurentiis M., De Placido S., Catalano G., Bianco A.R., Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 2002, 8:3438-3444.
9. Drake J.M., Graham N.A., Stoyanova T., Sedghi A., Goldstein A.S., Cai H., Smith D.A., Zhang H., Komisopoulou E., Huang J., Graeber T.G., Witte O.N. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc. Natl. Acad. Sci. USA 2012, 109:1643-1648.
10. Erdo S.L., Nemet L., Szporny L. The occurrence of GABA in vas deferens, prostate, epididymis, seminal vesicle and testicle of the rat. Acta Biol. Hung. 1983, 34:435-437.
11. Frolund B., Kristiansen U., Brehm L., Hansen A.B., Krogsgaard-Larsen P., Falch E. Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol. J. Med. Chem. 1995, 38:3287-3296.
12. Glynne-Jones E., Goddard L., Harper M.E. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum. Pathol. 1996, 27:688-694.
13. Guarino M. Src signaling in cancer invasion. J. Cell. Physiol. 2010, 223:14-26.
14. Hammarsten P., Karalija A., Josefsson A., Rudolfsson S.H., Wikstrom P., Egevad L., Granfors T., Stattin P., Bergh A. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin. Cancer Res. 2010, 16:1245-1255.
15. Hardt J., Larsson L.I., Hougaard D.M. Immunocytochemical evidence suggesting that diamine oxidase catalyzes biosynthesis of g-aminobutyric acid in antropyloric gastrin cells. J. Histochem. Cytochem. 2000, 48:839-846.
16. Hirano, D., Okada, Y., Minei, S., Takimoto, Y., Nemoto, N., 2004. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol., vol. 45, pp. 586-592 (discussion 592).
17. Hu Y., Ippolito J.E., Garabedian E.M., Humphrey P.A., Gordon J.I. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J. Biol. Chem. 2002, 277:44462-44474.
18. Humez S., Monet M., Legrand G., Lepage G., Delcourt P., Prevarskaya N. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr. Relat. Cancer 2006, 13:181-195.
19. Ippolito J.E., Xu J., Jain S., Moulder K., Mennerick S., Crowley J.R., Townsend R.R., Gordon J.I. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc. Natl. Acad. Sci. USA 2005, 102:9901-9906.
20. Ippolito J.E., Merritt M.E., Backhed F., Moulder K.L., Mennerick S., Manchester J.K., Gammon S.T., Piwnica-Worms D., Gordon J.I. Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers. Proc. Natl. Acad. Sci. USA 2006, 103:12505-12510.
21. Johnson S.K., Haun R.S. The g-aminobutyric acid A receptor pi subunit is overexpressed in pancreatic adenocarcinomas. JOP 2005, 6:136-142.
22. Johnstone T.B., Gu Z., Yoshimura R.F., Villegier A.S., Hogenkamp D.J., Whittemore E.R., Huang J.C., Tran M.B., Belluzzi J.D., Yakel J.L., Gee K.W. Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition. J. Pharmacol. Exp. Therm. 2011, 336:908-915.
23. Kleinrok Z., Matuszek M., Jesipowicz J., Matuszek B., Opolski A., Radzikowski C. GABA content and GAD activity in colon tumors taken from patients with colon cancer or from xenografted human colon cancer cells growing as s.c. tumors in athymic nu/nu mice. J. Physiol. Pharmacol. 1998, 49:303-310.
24. Kraus S., Benard O., Naor Z., Seger R. C-Src is activated by the epidermal growth factor receptor in a pathway that mediates JNK and ERK activation by gonadotropin-releasing hormone in COS7 cells. J. Biol. Chem. 2003, 278:32618-32630.
25. Kumar R., Srinivasan S., Pahari P., Rohr J., Damodaran C. Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. Mol. Cancer Ther. 2010, 9:2488-2496.
26. Li K., Xu E. The role and the mechanism of g-aminobutyric acid during central nervous system development. Neurosci. Bull. 2008, 24:195-200.
27. -DDCT method. Methods 2001, 25:402-408.
28. Matuszek M., Jesipowicz M., Kleinrok Z. GABA content and GAD activity in gastric cancer. Med. Sci. Monit. 2001, 7:377-381.
29. Miles R., Toth K., Gulyas A.I., Hajos N., Freund T.F. Differences between somatic and dendritic inhibition in the hippocampus. Neuron 1996, 16:815-823.
30. Mimeault M., Johansson S.L., Batra S.K. Pathobiological implications of the expression of EGFR, pAkt, NF-kB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One 2012, 7:e31919.
31. Napoleone P., Bronzetti E., Cavallotti C., Amenta F. Predominant epithelial localization of type A g-aminobutyric acid receptor sites within rat seminal vesicles and prostate glands. Pharmacology 1990, 41:49-56.
32. Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 1999, 274:17209-17218.
33. Peraldo-Neia C., Migliardi G., Mello-Grand M., Montemurro F., Segir R., Pignochino Y., Cavalloni G., Torchio B., Mosso L., Chiorino G., Aglietta M. Epidermal growth factor receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 2011, 11:31.
34. Sancar F., Czajkowski C. Allosteric modulators induce distinct movements at the GABA-binding site interface of the GABA-A receptor. Neuropharmacology 2011, 60:520-528.
35. Sirotnak F.M., She Y., Lee F., Chen J., Scher H.I. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin. Cancer Res. 2002, 8:3870-3876.
36. Soghomonian J.J., Martin D.L. Two isoforms of glutamate decarboxylase: why?. Trends Pharmacol. Sci. 1998, 19:500-505.
37. Takehara A., Hosokawa M., Eguchi H., Ohigashi H., Ishikawa O., Nakamura Y., Nakagawa H. G-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res. 2007, 67:9704-9712.
38. Tatarov O., Mitchell T.J., Seywright M., Leung H.Y., Brunton V.G., Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res. 2009, 15:3540-3549.
39. Taylor S.J., Shalloway D. Src and the control of cell division. Bioessays 1996, 18:9-11.
40. Vuky J., Porter C., Isacson C., Vaughan M., Kozlowski P., Picozzi V., Corman J. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 2009, 115:784-791.
41. Watanabe M., Maemura K., Oki K., Shiraishi N., Shibayama Y., Katsu K. G-aminobutyric acid (GABA) and cell proliferation: focus on cancer cells. Histol. Histopathol. 2006, 21:1135-1141.
42. Weinstein M.H., Partin A.W., Veltri R.W., Epstein J.I. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum. Pathol. 1996, 27:683-687.
43. White W.F., Snodgrass S.R. Isoguvacine binding, uptake, and release: relation to the GABA system. J. Neurochem. 1983, 40:1701-1708.
44. A receptor-associated protein. Genomics 2001, 74:408-413.
45. Yang Q., Titus M.A., Fung K.M., Lin H.K. 5a-Androstane-3a,17b-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. J. Cell. Biochem. 2008, 104:1612-1624.
46. Yu E.Y., Massard C., Gross M.E., Carducci M.A., Culine S., Hudes G., Posadas E.M., Sternberg C.N., Wilding G., Trudel G.C., Paliwal P., Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011, 77:1166-1171.
47. Zafrakas M., Chorovicer M., Klaman I., Kristiansen G., Wild P.J., Heindrichs U., Knuchel R., Dahl E. Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue. Int. J. Cancer 2006, 118:1453-1459.